Biological nanoparticles carrying the Hmda-7 gene are effective in inhibiting pancreatic cancer in vitro and in vivo

Zhu, Qingyun; Pan, Xinting; Sun, Yunbo; Wang, Zhengbin; Liu, Fuguo; Li, Aiqin; Zhao, Zhihui; Wang, Yunlong; Li, Kun; Mi, Liangyu
October 2017
PLoS ONE;10/6/2017, Vol. 12 Issue 10, p1
Academic Journal
Objectives: Pancreatic cancer is one of the most common malignancies of the digestive system, and remains a clinical challenge. This study aimed to assess the effects of bovine serum albumin (BSA) nanoparticles carrying the hMDA-7 gene (BSA-NP-hMDA-7) in the treatment of pancreatic cancer. Methods: BSA-NP-hMDA-7 was generated by nanotechnology and gene recombination technology. A total of 5 BXPC-3 or PANC-1 pancreatic cancer cell groups were examined, including Control, BSA-NPs, Empty vector, hMDA-7 plasmid, and hMDA-7 BSA-NPs groups, respectively. Proliferation and apoptosis of cultured cells were assessed by the MTT method and flow-cytometry, respectively. In addition, pancreatic cancer models were established with both cell lines in nude mice, and the expression profiles of hMDA-7 and VEGF in cancer tissues were measured by Western blot and immunohistochemistry. Results: BSA-NP-hMDA-7 nanoparticles were successfully generated, and significantly inhibited the proliferation of BXPC-3 and PANC-1 cells; in addition, apoptosis rates were higher in both cell lines after treatment with BSA-NP-hMDA-7 (P<0.05). Nude mouse xenograft studies indicated that treatment with BSA-NP-hMDA-7 nanoparticles resulted in decreased tumor size. Moreover, the hMDA-7 protein was found in tumor tissues after hMDA-7 gene transfection, while BSA-NP-hMDA-7 significantly suppressed VEGF expression in tumor tissues. Similar results were obtained for both BXPC-3 and PANC-1 xenograft models. Conclusion: BSA nanoparticles carrying the hMDA-7 gene effectively transfected BXPC-3 and PANC-1 pancreatic cancer cells, causing reduced cell proliferation and enhanced apoptosis in vitro. In mouse xenografts, BSA-NP-hMDA-7 treatment decreased tumor size and reduced VEGF expression. These findings indicated that BSA-NP-hMDA-7 might exert anticancer effects via VEGF suppression.


Related Articles

  • Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer. Beg, Muhammad Shaalan; Dwivedi, Alok Kumar; Ahmad, Syed Arif; Ali, Sadia; Olowokure, Olugbenga // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Introduction: Diabetes mellitus (DM) has the potential to impact the pathogenesis, treatment, and outcome of pancreatic cancer. This study evaluates the impact of DM on pancreatic cancer survival. Methods: We conducted a retrospective cohort study from the Veterans Affairs (VA) Central Cancer...

  • Gastrointestinal tumors.  // Annals of Oncology;Oct2010 Supplement 8, Vol. 21 Issue suppl_8, pviii225 

    No abstract available.

  • Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. Goulart, Bernardo H. L.; Clark, Jeffrey W.; Lauwers, Gregory Y.; Ryan, David P.; Grenon, Nina; Muzikansky, Alona; Zhu, Andrew X. // Journal of Hematology & Oncology;2009, Vol. 2, p1 

    Background: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5-6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival...

  • Hospital Webcasts Cancer Surgery Live.  // India -- West;5/9/2014, Vol. 39 Issue 25, pA44 

    The article reports on Gem Hospital and Research Center's webcast of pancreatic cancer surgery in Korea, Great Britain, Japan and the U.S.

  • Molecular Targeting in Pancreatic Cancer. Wadler, Scott // Reviews on Recent Clinical Trials;Jan2007, Vol. 2 Issue 1, p69 

    The mortality and morbidity of tumors of the upper GI tract are formidable with incidence and mortality nearly the same. Therefore, better therapies are necessary, and these are generally molecularly targeted therapies. This chapter focuses on the treatment of pancreatic cancer with targeted...

  • Gastrointestinal tumors, non-colorectal.  // Annals of Oncology;Sep2012 Supplement 9, Vol. 23 Issue suppl_9, pix224 

    No abstract available.

  • Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery. Gallmeier, Eike; Bader, Dominik C.; Kriegl, Lydia; Berezowska, Sabina; Seeliger, Hendrik; Göke, Burkhard; Kirchner, Thomas; Bruns, Christiane; De Toni, Enrico N. // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Introduction: Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not been...

  • Fluorescence-Guided Surgery in Combination with UVC Irradiation Cures Metastatic Human Pancreatic Cancer in Orthotopic Mouse Models. Hiroshima, Yukihiko; Maawy, Ali; Zhang, Yong; Sato, Sho; Murakami, Takashi; Yamamoto, Mako; Uehara, Fuminari; Miwa, Shinji; Yano, Shuya; Momiyama, Masashi; Chishima, Takashi; Tanaka, Kuniya; Bouvet, Michael; Endo, Itaru; Hoffman, Robert M. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    The aim of this study is to determine if ultraviolet light (UVC) irradiation in combination with fluorescence-guided surgery (FGS) can eradicate metastatic human pancreatic cancer in orthotopic nude–mouse models. Two weeks after orthotopic implantation of human MiaPaCa-2 pancreatic cancer...

  • Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. Lin, Mao; Yuan, Yuan-Ying; Liu, Shu-Peng; Shi, Juan-Juan; Long, Xin-An; Niu, Li-Zhi; Chen, Ji-Bing; Li, Qiao; Xu, Ke-Cheng // Journal of Cancer Research & Clinical Oncology;Oct2015, Vol. 141 Issue 10, p1827 

    Introduction: In this trial, we isolated and cultured pancreatic cancer stem cells (CSCs) to produce a vaccine and prospectively evaluated its safety and efficacy in low-, medium-, and high-dose groups. Material and methods: Between February and October 2014, we enrolled 90 patients who met the...

  • Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Kou, Tadayuki; Kanai, Masashi; Yamamoto, Michio; Xue, Peng; Mori, Yukiko; Kudo, Yasushi; Kurita, Akira; Uza, Norimitsu; Kodama, Yuzo; Asada, Masanori; Kawaguchi, Michiya; Masui, Toshihiko; Mizumoto, Masaki; Yazumi, Shujiro; Matsumoto, Shigemi; Takaori, Kyoichi; Morita, Satoshi; Muto, Manabu; Uemoto, Shinji; Chiba, Tsutomu // International Journal of Clinical Oncology;Feb2016, Vol. 21 Issue 1, p118 

    Background: We aimed to construct a prognostic model to predict survival in patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy using readily available pretreatment factors. Methods: The model was constructed using data from 306 consecutive patients with APC who...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics